Resin extract from Boswellia serrata tree containing pentacyclic triterpenic acids (boswellic acids), particularly AKBA (3-acetyl-11-keto-β-boswellic acid), that selectively inhibit 5-lipoxygenase (5-LOX) enzyme, shifting eicosanoid metabolism toward anti-inflammatory pathways. Used in cPNI wound healing and connective tissue repair protocols.
Boswellia's primary mechanism is non-redox, non-competitive inhibition of 5-LOX, the enzyme converting arachidonic acid to pro-inflammatory leukotrienes (LTB4, LTC4, LTD4, LTE4). Unlike NSAIDs (which block COX enzymes), Boswellia preserves prostacyclin and PGE2 production while preventing leukotriene synthesis. This creates an eicosanoid class switch toward resolution without gastrointestinal side effects. AKBA also: (1) Inhibits elastase and cathepsin G (proteases that degrade connective tissue), (2) Reduces NFκB activation (anti-inflammatory transcriptional effect), (3) Promotes GAG (glycosaminoglycan) synthesis in cartilage, (4) Improves microcirculation in inflamed tissues. The net effect is reduced inflammation, preserved tissue integrity, and enhanced healing.
Boswellia is prescribed in cPNI connective tissue protocols as an alternative to NSAIDs for managing inflammation without disrupting wound healing or causing leaky gut. Particularly valuable for: (1) Osteoarthritis and joint pain (preserves cartilage GAGs while reducing inflammation), (2) Post-surgical healing (anti-inflammatory without impairing resolution), (3) Inflammatory bowel disease (reduces leukotriene-driven intestinal inflammation), (4) Asthma (inhibits leukotriene-mediated bronchoconstriction). Typical dose: 300-500 mg standardized extract (60-65% boswellic acids) 2-3x daily.
- Contains boswellic acids, particularly AKBA (most potent 5-LOX inhibitor)
- Selectively inhibits 5-LOX enzyme, preventing leukotriene synthesis
- Does NOT inhibit COX enzymes (preserves prostacyclin, avoids GI bleeding)
- Reduces NFκB activation for transcriptional anti-inflammatory effects
- Inhibits tissue-degrading proteases (elastase, cathepsin G)
- Promotes GAG synthesis in cartilage
- No gastrointestinal side effects unlike NSAIDs
- Used for arthritis, IBD, asthma, post-surgical healing
- Typical dose: 300-500 mg (60-65% boswellic acids) 2-3x daily
- 5-LOX — enzyme selectively inhibited by Boswellia boswellic acids
- leukotrienes — pro-inflammatory mediators whose synthesis is blocked by Boswellia
- eicosanoid — Boswellia creates class switch from leukotrienes to prostacyclins
- NSAIDs — Boswellia provides anti-inflammatory effects without NSAID side effects
- COX enzymes — NOT inhibited by Boswellia (unlike NSAIDs), preserving beneficial prostaglandins
- NFκB — transcription factor inhibited by boswellic acids
- wound healing — supported by Boswellia's anti-inflammatory effects without impairing resolution
- leaky gut — NOT caused by Boswellia (unlike NSAIDs which damage intestinal barrier)
- osteoarthritis — treated with Boswellia for cartilage preservation and pain reduction
- inflammatory bowel disease — Boswellia reduces leukotriene-driven intestinal inflammation
- glycosaminoglycans — synthesis promoted by Boswellia in cartilage
- elastase — protease inhibited by Boswellia, reducing connective tissue degradation
- omega-3 fatty acids — synergistic with Boswellia for eicosanoid class switch
- inflammation — reduced by Boswellia via 5-LOX inhibition
- arachidonic acid — substrate whose conversion to leukotrienes is blocked by Boswellia
- connective tissue — protected and supported by Boswellia's anti-catabolic effects
- MSM — often combined with Boswellia in joint support protocols
- curcumin — botanical often combined with Boswellia for synergistic anti-inflammatory effects
- asthma — improved by Boswellia's inhibition of leukotriene-mediated bronchoconstriction
- specialised pro-resolving mediators — Boswellia supports resolution by preventing leukotriene dominance